# GNTbm-38

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/gntbm-38
Canonical HTML page: https://gethealthbrief.com/entity/gntbm-38

## Timeline

- **2027-Q2**: Data Readout — Expected preliminary safety results from the Phase I cohort.
- **2026-Q3**: Phase I Commencement — Anticipated start of patient recruitment for safety and dosage studies.
- **2026-03-05**: FDA IND Approval — The U.S. FDA approves the application to begin human clinical trials.
- **2025**: Preclinical Development — GNTbm completes laboratory and animal testing for GNTbm-38.

## Recent coverage (1 stories)

### GNTbm Secures FDA IND Approval for Phase I Trials of Anti-Cancer Drug GNTbm-38
2026-03-05 14:13:43 · Sentiment: Positive · Impact: 7/10 · Sources: 2

The U.S. FDA has granted Investigational New Drug (IND) approval to GNTbm for its self-developed anti-cancer candidate, GNTbm-38. This milestone allows the company to initiate Phase I clinical trials in the United States, marking its transition into a clinical-stage biopharmaceutical entity.
Full story: https://gethealthbrief.com/story/gntbm-fda-ind-approval-gntbm-38-phase-1

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.